Product Description
Remimazolam, a novel benzodiazepine created out of so-called soft drug development, is an ultrashort-acting intravenous sedative-hypnotic currently being investigated in clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27496519/)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Denmark, Korea, Netherlands, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Healthy Volunteers|Other
Phase 2: Anesthesia Related|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-004118-37 | P3 |
Active, not recruiting |
Other |
2025-02-28 |
|
| DA10030 | P3 |
Active, not recruiting |
Other |
2024-12-01 |
82% |
| HR7056-302 | P3 |
Completed |
Other |
2024-08-13 |
|
| NCT05836545 | P3 |
Not yet recruiting |
Healthy Volunteers |
2023-12-31 |